{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:59Z","timestamp":1791999479218,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40290-024-00549-4","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T21:54:28Z","timestamp":1741038868000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Disproportionality Analysis and Causal Inference in Drug Safety"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-1170","authenticated-orcid":false,"given":"Emil","family":"Scosyrev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Ponnuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"1","key":"549_CR1","first-page":"3","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Drug Saf. 2002;11(1):3\u201310.","journal-title":"Drug Saf"},{"issue":"8","key":"549_CR2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.995","volume":"13","author":"S Hennessy","year":"2004","unstructured":"Hennessy S. Disproportionality analyses of spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(8):503\u20134.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"549_CR3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"549_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1365-2125.2011.04087.x","volume":"72","author":"A de Boer","year":"2011","unstructured":"de Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol. 2011;72(6):909\u201311.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"549_CR5","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1007\/s40264-013-0106-y","volume":"36","author":"W DuMouchel","year":"2013","unstructured":"DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36(Suppl 1):S123\u201332.","journal-title":"Drug Saf"},{"key":"549_CR6","doi-asserted-by":"crossref","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul [Internet]. 2024, 3. https:\/\/www.frontiersin.org\/journals\/drug-safety-and-regulation\/articles\/10.3389\/fdsfr.2023.1323057\/full. Accessed 22 Dec 2024.","DOI":"10.3389\/fdsfr.2023.1323057"},{"issue":"1","key":"549_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0962280211403602","volume":"22","author":"I Zorych","year":"2013","unstructured":"Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39\u201356.","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"549_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415\u201322.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"549_CR9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384.","journal-title":"Drug Saf"},{"issue":"6","key":"549_CR10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"issue":"3","key":"549_CR11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000505376","volume":"43","author":"Y Song","year":"2020","unstructured":"Song Y, Xu YL, Lin Y, Zhao B, Sun Q. Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15\u00a0years. Oncol Res Treat. 2020;43(3):96\u2013102.","journal-title":"Oncol Res Treat."},{"issue":"7","key":"549_CR12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2019-0120","volume":"12","author":"F Hu","year":"2020","unstructured":"Hu F, Ye X, Zhai Y, Xu J, Guo X, Guo Z, Zhou X, Ruan Y, Zhuang Y, He J. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. Immunotherapy. 2020;12(7):531\u201340.","journal-title":"Immunotherapy"},{"issue":"4","key":"549_CR13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/fcp.12991","volume":"38","author":"JY Han","year":"2024","unstructured":"Han JY, Lee JM, Jung SY, Kim MS, Lee SW, Kronbichler A, Tizaoui K, Koyanagi A, Kim EY, Song K, Chae HW, Yon DK, Shin JI, Smith L. Comparison of agranulocytosis and anti-neutrophil cytoplasmic antibody-associated vasculitis caused by two antithyroid drugs: a pharmacovigilance study using the WHO international database. Fundam Clin Pharmacol. 2024;38(4):780\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"9","key":"549_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","volume":"45","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xie W, Wang L, Zhu X, Li J, Liu L, Zhu S, Wang L. Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis. Drug Saf. 2022;45(9):951\u20139.","journal-title":"Drug Saf"},{"key":"549_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109015","volume":"110","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system. Int Immunopharmacol. 2022;110: 109015.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"549_CR16","volume":"17","author":"Y Yang","year":"2022","unstructured":"Yang Y, Shu Y, Chen G, Yin Y, Li F, Li J. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax. PLoS ONE. 2022;17(12): e0278725.","journal-title":"PLoS ONE"},{"key":"549_CR17","first-page":"394632022114552","volume":"36","author":"X Ren","year":"2022","unstructured":"Ren X, Yan C, Tian L, Cui X. Haematopoietic cytopenia associated with cyclin-dependent kinase 4\/6 inhibitors: a real-world study of data from the food and drug administration adverse event reporting system database. Int J Immunopathol Pharmacol. 2022;36:3946320221145520.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"549_CR18","volume":"326","author":"Y Chen","year":"2023","unstructured":"Chen Y, Fan Q, Liu Y, Shi Y, Luo H. Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS. Psychiatry Res. 2023;326: 115300.","journal-title":"Psychiatry Res"},{"issue":"3","key":"549_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14740338.2022.2110234","volume":"22","author":"J Wu","year":"2023","unstructured":"Wu J, Huang J, Zhu J, He Z, Chen M, Gao S, Liang D, Yu X, Lu C. Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. Expert Opin Drug Saf. 2023;22(3):231\u20135.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"549_CR20","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/bcp.15869","volume":"90","author":"AT Jacob","year":"2024","unstructured":"Jacob AT, Kumar AH, Halivana G, Lukose L, Nair G, Subeesh V. Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database. Br J Clin Pharmacol. 2024;90(8):1804\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"549_CR21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11096-022-01527-z","volume":"45","author":"T Yamada","year":"2023","unstructured":"Yamada T, Kato R, Ijiri Y, Nishihara M, Neo M. Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors. Int J Clin Pharm. 2023;45(2):442\u201350.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"549_CR22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/jcph.2312","volume":"63","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wei Z, Zheng Y, Xie H, Cao W, Cai X, Huang J, Wu X. Disproportionality analysis of lenvatinib-caused gastrointestinal perforation in cancer patients: a pharmacovigilance analysis based on the US Food and Drug Administration Adverse Event Reporting System. J Clin Pharmacol. 2023;63(10):1133\u201340.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"549_CR23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","volume":"23","author":"J Li","year":"2024","unstructured":"Li J, Wang Y, Yang X, Zhu H, Jiang Z. Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database. Expert Opin Drug Saf. 2024;23(8):1061\u20137.","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"549_CR24","doi-asserted-by":"crossref","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","volume":"4","author":"S Zou","year":"2024","unstructured":"Zou S, Ouyang M, Zhao Y, Cheng Q, Shi X, Sun M. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases. Front Pharmacol. 2024;4(15):1392914.","journal-title":"Front Pharmacol"},{"key":"549_CR25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jclinepi.2021.06.022","volume":"138","author":"A Mouffak","year":"2021","unstructured":"Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL, Khouri C. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021;138:73\u20139.","journal-title":"J Clin Epidemiol"},{"key":"549_CR26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","volume":"139","author":"C Khouri","year":"2021","unstructured":"Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol. 2021;139:191\u20138.","journal-title":"J Clin Epidemiol"},{"key":"549_CR27","unstructured":"US Food and Drug Administration. ICH E9 (R1). Estimands and sensitivity analysis in clinical trials; 2017. https:\/\/www.fda.gov\/media\/108698\/download. Accessed 09 Sept 2023."},{"key":"549_CR28","unstructured":"European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. EMA\/CHMP\/ICH\/436221\/2017; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Accessed 10 Sept 2023."},{"issue":"24","key":"549_CR29","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target Trial Emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"issue":"2","key":"549_CR30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ije\/31.2.422","volume":"31","author":"G Maldonado","year":"2002","unstructured":"Maldonado G, Greenland S. Estimating causal effects. Int J Epidemiol. 2002;31(2):422\u20139.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"549_CR31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/insr.12213","volume":"85","author":"E Scosyrev","year":"2017","unstructured":"Scosyrev E, Bancken F. Expected precision of estimation and probability of ruling out a hypothesis based on a confidence interval. Int Stat Rev. 2017;85(3):455\u201372.","journal-title":"Int Stat Rev"},{"key":"549_CR32","doi-asserted-by":"publisher","unstructured":"Noguchi Y, Tachi T, Yoshimura T. Caveats of covariate adjustment in disproportionality analysis for best practices. Drug Saf. 2024. https:\/\/doi.org\/10.1007\/s40264-024-01473-x. Epub ahead of print. PMID: 39154117.","DOI":"10.1007\/s40264-024-01473-x"},{"key":"549_CR33","unstructured":"Duggirala HJ, Tonning JM, Smith E, et al. Data mining at FDA\u2014white paper. Us Food and Drug Administration; 2018. https:\/\/www.fda.gov\/science-research\/data-mining\/data-mining-fda-white-paper. Accessed 22 Dec 2024."},{"key":"549_CR34","unstructured":"European Medicines Agency. EudraVigilance user manual. Version 17-Feb-2021. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/eudravigilance-user-manual-marketing-authorisation-holders_en.pdf. Accessed 22 Dec 2024."},{"issue":"14","key":"549_CR35","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","volume":"21","author":"PGM Van Der Heijden","year":"2002","unstructured":"Van Der Heijden PGM, Van Puijenbroek EP, Van Buuren S, Van Der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med. 2002;21(14):2027\u201344.","journal-title":"Stat Med"},{"issue":"1","key":"549_CR36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.1657","volume":"14","author":"P Ghosh","year":"2015","unstructured":"Ghosh P, Dewanji A. Effect of reporting bias in the analysis of spontaneous reporting data. Pharm Stat. 2015;14(1):20\u20135.","journal-title":"Pharm Stat"},{"key":"549_CR37","doi-asserted-by":"crossref","unstructured":"Fusaroli M, Mitchell J, Rudolph A, Rocca E, Fusaroli R. Causal inference tools for pharmacovigilance: using causal graphs to identify and address biases in disproportionality analysis. OSF; 2024. https:\/\/osf.io\/preprints\/osf\/h5w9u. Accessed 22 Feb 2024.","DOI":"10.31219\/osf.io\/h5w9u"},{"issue":"6","key":"549_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539\u201346.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"549_CR39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/2042098616685010","volume":"8","author":"M Hauben","year":"2017","unstructured":"Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8(5):145\u201356.","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"549_CR40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore\u2014a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583\u201390.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"549_CR41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387.","journal-title":"Drug Saf"},{"issue":"1","key":"549_CR42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","volume":"39","author":"MA Maci\u00e1-Mart\u00ednez","year":"2016","unstructured":"Maci\u00e1-Mart\u00ednez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39(1):29\u201343.","journal-title":"Drug Saf"},{"issue":"10","key":"549_CR43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40264-015-0314-8","volume":"38","author":"Y Li","year":"2015","unstructured":"Li Y, Ryan PB, Wei Y, Friedman C. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015;38(10):895\u2013908.","journal-title":"Drug Saf"},{"issue":"6","key":"549_CR44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/11534410-000000000-00000","volume":"33","author":"Y Alvarez","year":"2010","unstructured":"Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475\u201387.","journal-title":"Drug Saf"},{"issue":"10","key":"549_CR45","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70028","volume":"33","author":"RJ Desai","year":"2024","unstructured":"Desai RJ, Marsolo K, Smith J, Carrell D, Penfold R, Pillai HS, Lii J, Ngan K, Winter R, Adgent M, Ramaprasan A, Driscoll MR, Scarnecchia D, Kiernan D, Draper C, Lyons JG, Khurshid A, Maro JC, Zimmerman R, Brown J, Bright P, Hern\u00e1ndez-Mu\u00f1oz JJ, Matheny ME, Schneeweiss S. The FDA sentinel real world evidence data enterprise (RWE-DE). Pharmacoepidemiol Drug Saf. 2024;33(10):e70028.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-024-00549-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:42:00Z","timestamp":1744004520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-024-00549-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40290-024-00549-4","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"29 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employed by Novartis. Opinions expressed in this paper are those of the authors and do not necessarily represent an official position of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed substantially to the conception of the work. ES wrote the first draft of the work. SB, DJ, AP, and CM performed critical revisions. All authors have read and approve the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}